SCHEMBL2213283

SCHEMBL2213283

CC(C)(C)OC(=O)Nc1ccc(Nc2nc(-c3ccc(-c4cccc([N+](=O)[O-])c4)cc3)cc3ccnn23)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.42
PLAU P00749 1/20 0.42
PLAT P00750 1/20 0.42
ABCB1 P08183 2/20 0.41
ABCC1 P33527 1/20 0.40
BCL2 P10415 2/20 0.40
BECN1 Q14457 2/20 0.40
SIRT2 Q8IXJ6 1/20 0.39
CYP17A1 P05093 3/20 0.39
PLK1 P53350 1/20 0.38
MAPT P10636 2/20 0.37
ALOX5 P09917 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PRMT1 Q99873 1/20 0.37
CNR1 P21554 1/20 0.37
CSNK2A1 P68400 1/20 0.37
GNRHR P30968 1/20 0.37
VCP P55072 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2214223 0.87 PLG (0.42) PLGPLAUPLATABCB1ABCC1
SCHEMBL2216214 0.86 CYP17A1 (0.41) CYP17A1MAP4K4CHRM1
SCHEMBL2215485 0.86 PLAU (0.42) PLGPLAUPLATCYP17A1NPC1
SCHEMBL2216413 0.86 CYP17A1 (0.49) ABCB1ABCC1CYP17A1PLK1MAPT
SCHEMBL2213436 0.84 CYP17A1 (0.43) CYP17A1RAB9AMAP4K4CHRM1
SCHEMBL2881793 0.83 CSNK2A1 (0.46) PLGPLAUPLATABCB1PLK1
SCHEMBL2882070 0.83 PLG (0.43) PLGPLAUPLATABCB1ABCC1
SCHEMBL2881795 0.83 PLK1 (0.44) PLK1MAPTRAB9ACSNK2A1VCP
SCHEMBL2214224 0.83 BCL2 (0.43) BCL2BECN1CYP17A1CHRM1
SCHEMBL2253893 0.79 PLG (0.44) PLGPLAUPLATABCB1ABCC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 PLG 4568/4885PLAU 4610/4885PLAT 4238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.